middle.news
Can ARG-007 Transform Stroke Recovery? Promising Phase 2 Functional Gains Revealed
8:41am on Wednesday 15th of October, 2025 AEDT
•
Healthcare
Read Story
Can ARG-007 Transform Stroke Recovery? Promising Phase 2 Functional Gains Revealed
8:41am on Wednesday 15th of October, 2025 AEDT
Key Points
ARG-007 treated patients showed trends toward better cognition and daily living independence
Functional endpoints prioritized over imaging for upcoming Phase 3 trial design
Phase 2 trial underpowered but reveals clinically meaningful signals
Plans underway for a focused Phase 2b trial with regulatory and pharma input
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE